Overstepping the Boundaries of Percutaneous Pulmonary Valve Placement Guidelines

Percutaneous pulmonary valve implantation

INTRODUCTION Percutaneous pulmonary valve implantation (PPVI) is one of the most exciting recent developments in the treatment of structural heart disease and has evolved as an attractive alternative to surgery in patients with dysfunctional right ventricle-pulmonary artery conduits. Although surgical pulmonary valve replacement is associated with low morbidity and mortality rates, there are ma...

Percutaneous Pulmonary Valve Implantation

Pulmonary regurgitation (PR) is a frequent sequelae after repair of tetralogy of Fallot, pulmonary atresia, truncus arteriosus, Rastelli and Ross operation. Due to patient growth and conduit degeneration, these conduits have to be changed frequently due to regurgitation or stenosis. However, morbidity is significant in these repeated operations. To prolong conduit longevity, bare-metal stenting...

Percutaneous implantation of a pulmonary valve.

Percutaneous Pulmonary Valve Implantation Alters Electrophysiologic Substrate

BACKGROUND Percutaneous pulmonary valve implantation (PPVI) is first-line therapy for some congenital heart disease patients with right ventricular outflow tract dysfunction. The hemodynamics improvements after PPVI are well documented, but little is known about its effects on the electrophysiologic substrate. The objective of this study is to assess the short- and medium-term electrophysiologi...

Percutaneous Pulmonary Valve Implantation— Clinical Context

Percutaneous Pulmonary Valve Implantation— Clinical Context For many congenital heart defects treated in infancy (eg, tetralogy of Fallot, transposition of the great arteries, double outlet right ventricle), long-term right ventricular outflow tract (RVOT) dysfunction, in the form of pulmonary stenosis and regurgitation, is a common finding as patients become older (older children, adolescents,...